A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' compared with Pulmicort (budesonide) Turbuhaler 200 μg twice daily plus terbutaline Turbuhaler 0.4 mg 'as needed'
2020-07-04
عنوان الدراسة
A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' compared with Pulmicort (budesonide) Turbuhaler 200 μg twice daily plus terbutaline Turbuhaler 0.4 mg 'as needed'
داعم الدراسة
AstraZeneca
دواء الدراسة
Budesonide / Formoterol / Budesonide / Terbutaline
رقم بروتوكول الدراسة
D589SC00003
حالة الدراسة
Ongoing
موقع الدراسة
Armed Forces Hospital (Dhahran), King Fahad Specialist Hospital (Dammam), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad University Hospital (Al-Khobar), King Faisal Specialist Hospital and Research Center (Jeddah)
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。